Cargando…

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression

SIMPLE SUMMARY: The aim of this innovative review is to highlight the treatment strategies beyond immune-checkpoint inhibitor (ICI)-based first-line therapy failure according to different patterns of progression (i.e., oligo or systemic progression) and to discuss the ongoing and potential future th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prelaj, Arsela, Pircher, Chiara Carlotta, Massa, Giacomo, Martelli, Valentino, Corrao, Giulia, Lo Russo, Giuseppe, Proto, Claudia, Ferrara, Roberto, Galli, Giulia, De Toma, Alessandro, Genova, Carlo, Jereczek-Fossa, Barbara Alicja, de Braud, Filippo, Garassino, Marina Chiara, Rebuzzi, Sara Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999258/ https://www.ncbi.nlm.nih.gov/pubmed/33803958 http://dx.doi.org/10.3390/cancers13061300

Ejemplares similares

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021)

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)

Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
por: Occhipinti, Mario, et al.
Publicado: (2021)

SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020)

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
por: Prelaj, Arsela, et al.
Publicado: (2020)

Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy
por: Prelaj, Arsela, et al.
Publicado: (2022)

EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
por: Prelaj, Arsela, et al.
Publicado: (2019)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
por: Prelaj, Arsela, et al.
Publicado: (2023)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
por: Lo Russo, Giuseppe, et al.
Publicado: (2017)

Unraveling Mitochondrial Determinants of Tumor Response to Radiation Therapy
por: Zaffaroni, Mattia, et al.
Publicado: (2022)

COVID-19 manifestation in the oral cavity – a narrative literature review
por: Kusiak, Aida, et al.
Publicado: (2021)

Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy
por: Corrao, Giulia, et al.
Publicado: (2023)

Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer
por: Marvaso, Giulia, et al.
Publicado: (2022)

MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review
por: Lo Russo, Giuseppe, et al.
Publicado: (2018)

Automatic Segmentation with Deep Learning in Radiotherapy
por: Isaksson, Lars Johannes, et al.
Publicado: (2023)

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature
por: Prelaj, Arsela, et al.
Publicado: (2019)

Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors
por: Cha, Yu Jin, et al.
Publicado: (2017)

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2019)

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
por: Prelaj, Arsela, et al.
Publicado: (2022)

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Investigating Nutritional and Inflammatory Status as Predictive Biomarkers in Oligoreccurent Prostate Cancer—A RADIOSA Trial Preliminary Analysis
por: Zaffaroni, Mattia, et al.
Publicado: (2023)

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group
por: Marvaso, Giulia, et al.
Publicado: (2023)

Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy
por: Prelaj, Arsela, et al.
Publicado: (2019)

COVID-19 impact in radiotherapy practice in an oncology hub: a screenshot from Lombardy, Italy
por: Corrao, Giulia, et al.
Publicado: (2020)

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
por: Lo Russo, G., et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Altered fractionation in radiation therapy for breast cancer in the elderly: are we moving forward?
por: Pinzi, Valentina, et al.
Publicado: (2020)

Cyberknife Radiosurgery for Prostate Cancer after Abdominoperineal Resection (CYRANO): The Combined Computer Tomography and Electromagnetic Navigation Guided Transperineal Fiducial Markers Implantation Technique
por: Vavassori, Andrea, et al.
Publicado: (2023)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome
por: Riva, Giulia, et al.
Publicado: (2017)

Machine Learning-Based Models for Prediction of Toxicity Outcomes in Radiotherapy
por: Isaksson, Lars J., et al.
Publicado: (2020)

Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs
por: Lussier, Yves A., et al.
Publicado: (2012)

Oligo-Fucoidan Prevents M2 Macrophage Differentiation and HCT116 Tumor Progression
por: Chen, Li-Mei, et al.
Publicado: (2020)

(Semi)-Synthetic Fucosylated Chondroitin Sulfate Oligo- and Polysaccharides
por: Vessella, Giulia, et al.
Publicado: (2020)

Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience
por: Valeriani, Maurizio, et al.
Publicado: (2019)

Whole-body magnetic resonance imaging: technique, guidelines and key applications
por: Summers, Paul, et al.
Publicado: (2021)

Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC
por: Prelaj, Arsela, et al.
Publicado: (2017)

Combination of dabrafenib and radiotherapy: could skin toxicity be affected by different irradiation techniques?
por: Alterio, Daniela, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t1l6mhc4o4jlqb6b5hkjuon2t3